Back to top
more

KALEIDO BIOSCI (KLDO)

(Delayed Data from NSDQ)

$14.45 USD

14.45
10,764

+0.15 (1.05%)

Updated May 3, 2019 04:00 PM ET

After-Market: $14.25 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Reata's (RETA) Q4 Earnings Miss Mark, Revenues Decline Y/Y

by Zacks Equity Research

Reata (RETA) reports a wider-than-expected loss in the fourth quarter of 2021 while revenues are slightly lower than estimates.

Editas' (EDIT) Q4 Loss Narrows, Revenues Trump Estimates

by Zacks Equity Research

Editas (EDIT) reports narrower-than-expected loss in the fourth quarter of 2021 while its revenues beat estimates. Focus remains on the development of lead candidate, EDIT-101.

Global Blood's (GBT) Q4 Earnings Miss Mark, Revenues Rise Y/Y

by Zacks Equity Research

Global Blood (GBT) reports wider-than-expected loss in the fourth quarter of 2021 while revenues are slightly above estimates.

Kaleido Biosciences, Inc. (KLDO) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

by Zacks Equity Research

Kaleido Biosciences, Inc. (KLDO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Novavax (NVAX) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

On Novavax's (NVAX) fourth-quarter earnings call, investor focus is likely to be on the initial sales numbers of the company's COVID-19 vaccine.

Is a Beat Likely for Perrigo (PRGO) This Earnings Season?

by Zacks Equity Research

Perrigo's (PRGO) new products as well as products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.

Avid (CDMO) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Avid Bioservices (CDMO) is set to provide updates on its CDMO business and other such developments when it reports earnings results for third quarter of fiscal 2022.

    Bristol Myers' (BMY) Breyanzi sBLA Gets FDA's Priority Review

    by Zacks Equity Research

    The FDA accepts Bristol Myers' (BMY) sBLA for Breyanzi under a priority review as a second-line treatment for relapsed/refractory large B-cell lymphoma. A decision is due on Jun 24, 2022.

    Blueprint Medicines (BPMC) Q4 Loss Widens, Revenues Top Mark

    by Zacks Equity Research

    Blueprint Medicines (BPMC) misses on earnings while revenue beat estimates for the fourth quarter of 2021. Stock down.

    Alkermes' (ALKS) Q4 Earnings and Revenues Beat Estimates

    by Zacks Equity Research

    Alkermes (ALKS) rides high on both earnings and sales beating estimates in the fourth quarter of 2021.

    Orphazyme (ORPH) Up on Plans of NDA Resubmission for Rare Drug

    by Zacks Equity Research

    Orphazyme (ORPH) is looking to resubmit its NDA for arimoclomol to the FDA for the treatment of Niemann-Pick disease type C in the United States. Shares rise.

    Here's Why Kaleido Biosciences, Inc. (KLDO) is Poised for a Turnaround After Losing 33.2% in 4 Weeks

    by Zacks Equity Research

    Kaleido Biosciences, Inc. (KLDO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

    Kaleido Biosciences, Inc. (KLDO) Sees Hammer Chart Pattern: Time to Buy?

    by Zacks Equity Research

    Kaleido Biosciences, Inc. (KLDO) recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom.

    Here's Why Kaleido Biosciences, Inc. (KLDO) Is a Great 'Buy the Bottom' Stock Now

    by Zacks Equity Research

    Kaleido Biosciences, Inc. (KLDO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

    Kaleido Biosciences, Inc. (KLDO) Reports Q3 Loss, Misses Revenue Estimates

    by Zacks Equity Research

    Kaleido Biosciences, Inc. (KLDO) delivered earnings and revenue surprises of 1.82% and -58.40%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

    Down 23.6% in 4 Weeks, Here's Why Kaleido Biosciences, Inc. (KLDO) Looks Ripe for a Turnaround

    by Zacks Equity Research

    Kaleido Biosciences, Inc. (KLDO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

    Kaleido Biosciences, Inc. (KLDO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

    by Zacks Equity Research

    Kaleido Biosciences, Inc. (KLDO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Kaleido Biosciences, Inc. (KLDO) Reports Q2 Loss, Lags Revenue Estimates

    by Zacks Equity Research

    Kaleido Biosciences, Inc. (KLDO) delivered earnings and revenue surprises of 5.08% and -15.60%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

    Kaleido Biosciences, Inc. (KLDO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

    by Zacks Equity Research

    Kaleido Biosciences, Inc. (KLDO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    CytoDyn (CYDY) Files New Protocol With FDA for COVID-19 Study

    by Zacks Equity Research

    CytoDyn (CYDY) submits a new protocol with the regulatory body in the United States to study a higher dose of leronlimab for severely-infected COVID-19 patients.

    Biotech Stock Roundup: BLUE/BMY's CAR T Therapy Nod, KLDO's COVID-19 Study News & More

    by Zacks Equity Research

    The biotech sector gains prominence with new product approvals from bluebird (BLUE)/Bristol Myers Squibb (BMY) and other coronavirus updates.

    Kaleido (KLDO) Reports Positive Results from COVID-19 Study

    by Zacks Equity Research

    Kaleido (KLDO) announces impressive results from a study on KB109 in patients with mild-to-moderate COVID-19.

    Kaleido Biosciences (KLDO) Sees Hammer Chart Pattern: Time to Buy?

    by Zacks Equity Research

    Kaleido Biosciences (KLDO) has been struggling lately, but the selling pressure may be coming to an end soon.

    New Strong Sell Stocks for November 13th

    by Zacks Equity Research

    Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

    Is Kaleido Biosciences (KLDO) Stock Outpacing Its Medical Peers This Year?

    by Zacks Equity Research

    Is (KLDO) Outperforming Other Medical Stocks This Year?